Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03069378 | A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma | PHASE2 | ACTIVE NOT_RECRUITING | 41 | — | — | Mar 3, 2017 | Mar 1, 2026 | Oct 29, 2025 | 5 | United States |
(complete response + partial response) RECIST 1.1. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
| Arm | Type | Description |
|---|---|---|
| Talimogene Laherparepvec (T-VEC) Administered with Pembrolizu | EXPERIMENTAL | Patients will initiate treatment with talimogene laherparepvec given intralesionally and pembrolizumab. |
| Name | Type | Description |
|---|---|---|
| Talimogene Laherparepvec (T-VEC) | DRUG | Talimogene laherparepvec treatment will be given at Day 1 Week 1, and every 3 weeks thereafter . |
| Pembrolizumab | DRUG | Pembrolizumab will be given at Day 1 week 1 and every 3 weeks thereafter. |
Inclusion Criteria: * Male or female age ≥ 18 years at the time of informed consent * Be willing and able to provide written informed consent/assent for the trial * Be willing to comply with treatment protocol * Subjects must have a histologically confirmed metastatic and/or locally advanced inoper...